,in 2020.txt,in 2021.txt
the,388.0,443.0
of,369.0,360.0
Unnamed: 48,,351.0
and,319.0,295.0
in,242.0,280.0
with,141.0,142.0
to,129.0,131.0
patients,72.0,115.0
a,84.0,101.0
was,85.0,92.0
for,86.0,71.0
were,76.0,70.0
is,37.0,46.0
on,37.0,45.0
or,22.0,39.0
study,41.0,37.0
by,48.0,36.0
we,40.0,35.0
countries,2.0,34.0
that,33.0,33.0
abstract,32.0,33.0
this,21.0,32.0
at,31.0,31.0
from,32.0,30.0
an,24.0,28.0
pd,29.0,27.0
de,,26.0
–,27.0,25.0
using,14.0,25.0
use,4.0,24.0
disease,28.0,24.0
as,25.0,23.0
treatment,18.0,23.0
no,8.0,21.0
after,15.0,20.0
not,16.0,20.0
all,8.0,20.0
be,14.0,19.0
are,24.0,19.0
phase,3.0,18.0
p  ,11.0,18.0
eculizumab,,18.0
data,15.0,17.0
between,10.0,16.0
survival,14.0,16.0
therapy,9.0,16.0
rs,5.0,16.0
tdm,,16.0
results,22.0,16.0
care,1.0,15.0
responses,3.0,15.0
these,11.0,15.0
effects,7.0,14.0
neurons,6.0,14.0
population,4.0,14.0
pain,2.0,14.0
prevent,,14.0
analysis,13.0,14.0
months,19.0,13.0
have,8.0,13.0
also,10.0,13.0
response,15.0,13.0
expression,22.0,13.0
median,12.0,13.0
outcomes,6.0,13.0
effect,11.0,13.0
vascular,,13.0
cells,7.0,13.0
y,,12.0
relapse,2.0,12.0
grade,4.0,12.0
its,4.0,12.0
cr,5.0,12.0
observed,11.0,12.0
reduction,8.0,12.0
associated,14.0,12.0
  ,,12.0
compared,20.0,12.0
received,5.0,11.0
activity,6.0,11.0
nsb,,11.0
but,7.0,11.0
adjuvant,,11.0
rats,20.0,11.0
increased,18.0,11.0
cancer,1.0,11.0
risk,14.0,11.0
brain,9.0,10.0
trial,4.0,10.0
hd,,10.0
asian,,10.0
-,1.0,10.0
based,3.0,10.0
health,4.0,10.0
objective,3.0,10.0
may,15.0,10.0
chronic,3.0,10.0
high,4.0,9.0
most,11.0,9.0
increase,7.0,9.0
had,13.0,9.0
con,,9.0
la,,9.0
blood,12.0,9.0
both,13.0,9.0
within,2.0,9.0
versus,8.0,9.0
en,,9.0
acute,10.0,9.0
our,12.0,9.0
who,5.0,9.0
significant,7.0,9.0
motion,,9.0
sound,,9.0
however,5.0,9.0
taar,,9.0
their,8.0,9.0
surgery,,9.0
mirna-,,9.0
methods,17.0,9.0
only,11.0,9.0
ptb,,9.0
buspirone,,9.0
size,7.0,9.0
stage,2.0,9.0
levels,11.0,9.0
gcase,,9.0
clinical,16.0,9.0
studies,6.0,8.0
level,14.0,8.0
atezolizumab,,8.0
serum,3.0,8.0
than,11.0,8.0
groups,8.0,8.0
pandemic,6.0,8.0
including,12.0,8.0
model,5.0,8.0
adverse,7.0,8.0
visual,4.0,8.0
used,7.0,8.0
respectively,11.0,8.0
placebo,3.0,8.0
more,10.0,8.0
number,4.0,8.0
dose,1.0,8.0
system,5.0,8.0
quality,1.0,8.0
spatial,1.0,8.0
bariatric,,8.0
tnf-α,1.0,8.0
mor,,8.0
vs,2.0,8.0
myocardial,,8.0
glycogen,,8.0
aqp,,8.0
nmosd,,8.0
chemotherapy,1.0,8.0
subgroup,,8.0
which,9.0,8.0
scarb,,8.0
time,8.0,8.0
patterns,6.0,8.0
suicide,,8.0
changes,14.0,8.0
areas,,8.0
one,8.0,8.0
could,5.0,8.0
stigma,,8.0
ambroxol,,8.0
days,7.0,8.0
laser,2.0,7.0
nts,,7.0
plants,,7.0
age,23.0,7.0
mirna-а,,7.0
dolor,,7.0
findings,6.0,7.0
reu,,7.0
leukemia,5.0,7.0
background,5.0,7.0
can,3.0,7.0
group,33.0,7.0
low,5.0,7.0
expressed,,7.0
scz,,7.0
cell,8.0,7.0
processing,,7.0
cccooh,3.0,7.0
pelvic,,7.0
carboxylated,1.0,7.0
lorlatinib,6.0,7.0
involved,2.0,7.0
showed,3.0,7.0
it,7.0,7.0
higher,7.0,7.0
similar,1.0,7.0
hiv,4.0,7.0
ci,8.0,7.0
other,10.0,7.0
studied,8.0,7.0
crónico,,7.0
type,2.0,7.0
active,5.0,7.0
status,3.0,7.0
primary,4.0,7.0
pélvico,,7.0
respiratory,3.0,7.0
function,10.0,6.0
del,,6.0
thus,2.0,6.0
synchronization,,6.0
nct,1.0,6.0
/,3.0,6.0
tratamiento,,6.0
lung,2.0,6.0
refractory,,6.0
controls,8.0,6.0
gvhd,2.0,6.0
prostate,,6.0
four,2.0,6.0
th,,6.0
safety,7.0,6.0
disorder,1.0,6.0
range,3.0,6.0
gd,6.0,6.0
activation,6.0,6.0
two,8.0,6.0
inhibitory,,6.0
patient,5.0,6.0
years,12.0,6.0
randomized,6.0,6.0
rate,5.0,6.0
conclusion,9.0,6.0
enrolled,4.0,6.0
impact,1.0,6.0
three,10.0,6.0
zone,,6.0
oscillations,,6.0
shown,1.0,6.0
key,1.0,6.0
area,1.0,6.0
potential,5.0,6.0
found,8.0,6.0
supportive,,6.0
characterized,6.0,6.0
revealed,7.0,6.0
decreased,5.0,6.0
due,2.0,6.0
there,6.0,6.0
ii–iiia,,6.0
each,5.0,6.0
overall,11.0,6.0
best,,6.0
fullerene,3.0,6.0
reaction,2.0,6.0
receptors,4.0,6.0
se,,5.0
evaluate,3.0,5.0
tiers,,5.0
russia,3.0,5.0
mice,7.0,5.0
residues,,5.0
agonist,1.0,5.0
difference,7.0,5.0
early,14.0,5.0
measures,1.0,5.0
coherence,1.0,5.0
el,,5.0
concomitant,,5.0
-fold,2.0,5.0
cross-sectional,,5.0
expressions,,5.0
tumour,,5.0
covid-,12.0,5.0
artery,,5.0
expected,,5.0
estimated,1.0,5.0
suicides,,5.0
been,7.0,5.0
participants,7.0,5.0
glucose,,5.0
nitric,,5.0
oxide,,5.0
didrogesterona,,5.0
documented,,5.0
subgroups,,5.0
least,4.0,5.0
crs,,5.0
country,,5.0
open-label,1.0,5.0
toxicity,,5.0
significantly,3.0,5.0
regimens,1.0,5.0
dopamine,10.0,5.0
included,2.0,5.0
substance,2.0,5.0
events,6.0,5.0
pt-cy,,5.0
further,4.0,5.0
disease-free,1.0,5.0
structure,1.0,5.0
gba,2.0,5.0
dydrogesterone,,5.0
conclusions,4.0,5.0
effective,1.0,5.0
coronary,1.0,5.0
los,,5.0
association,7.0,5.0
transmission,,5.0
setting,2.0,5.0
pain-related,,5.0
abdominal,,5.0
technique,1.0,5.0
first-episode,,5.0
yoda,,5.0
availability,,5.0
interventions,1.0,5.0
reduce,4.0,5.0
gba-pd,,5.0
bone,5.0,5.0
nasal,,5.0
survey,,5.0
affordability,,5.0
development,6.0,5.0
accessibility,,5.0
incidence,4.0,5.0
cumulative,2.0,5.0
during,11.0,5.0
p,19.0,5.0
continuous,,5.0
endometriosis,,5.0
new,3.0,5.0
bdnf,,5.0
eeg,,5.0
six,5.0,5.0
n  ,3.0,5.0
specific,5.0,5.0
surface,1.0,5.0
method,6.0,5.0
without,6.0,5.0
well,5.0,5.0
donor,1.0,5.0
piezo,,5.0
mortality,3.0,4.0
control,3.0,4.0
reporting,,4.0
parameters,3.0,4.0
power,,4.0
diabetes,4.0,4.0
hr  ,,4.0
mellitus,2.0,4.0
proton,,4.0
regímenes,,4.0
option,,4.0
haplo-hct,3.0,4.0
nsclc,9.0,4.0
complex,3.0,4.0
 w,,4.0
transplantation,7.0,4.0
diode,,4.0
frequencies,,4.0
drugs,,4.0
serious,1.0,4.0
infarct,,4.0
monitoring,,4.0
 nm,,4.0
free,1.0,4.0
negative,1.0,4.0
translocation,,4.0
bdfs,,4.0
source,1.0,4.0
outcome,6.0,4.0
stem,2.0,4.0
performed,5.0,4.0
lower,10.0,4.0
people,1.0,4.0
them,,4.0
large,1.0,4.0
alk,7.0,4.0
moderate,2.0,4.0
cyclical,,4.0
mechanisms,10.0,4.0
oral,1.0,4.0
ist,,4.0
sexual,1.0,4.0
molecular,6.0,4.0
tumours,1.0,4.0
analyzed,4.0,4.0
obtained,4.0,4.0
lysosomal,4.0,4.0
glucocerebrosidase,1.0,4.0
mutations,2.0,4.0
pwid,,4.0
maintenance,,4.0
did,2.0,4.0
differences,2.0,4.0
dialysis,,4.0
common,8.0,4.0
provide,3.0,4.0
intervention,1.0,4.0
mirna-a,,4.0
resected,,4.0
available,3.0,4.0
low-income,,4.0
excitatory,2.0,4.0
present,4.0,4.0
optica,,4.0
impower,,4.0
spectrum,,4.0
molecule,1.0,4.0
gene,8.0,4.0
evidence,6.0,4.0
analyses,1.0,4.0
neuromyelitis,,4.0
mode,1.0,4.0
measured,1.0,4.0
-year,6.0,4.0
cajal-retzius,,4.0
types,,4.0
follow-up,8.0,4.0
proteins,3.0,4.0
iqr,,4.0
migraine,4.0,4.0
molecules,3.0,4.0
evaluated,4.0,4.0
mg/m,,4.0
across,1.0,4.0
prophylaxis,,4.0
million,,4.0
enzyme,,4.0
kidney,1.0,4.0
such,7.0,4.0
july,,4.0
worldwide,,4.0
aimed,2.0,4.0
aml,,4.0
receive,2.0,4.0
occurring,,4.0
assigned,1.0,4.0
index,2.0,4.0
same,2.0,4.0
contrast,1.0,4.0
recurrence,,4.0
velocity,1.0,4.0
rituximab,,4.0
per,3.0,4.0
evoked,2.0,4.0
n,2.0,4.0
receiving,2.0,4.0
trigeminovascular,5.0,4.0
various,2.0,4.0
south,,4.0
prolonged,2.0,4.0
asymmetry,,4.0
high-income,,4.0
binuclear,,4.0
factor,2.0,4.0
has,7.0,4.0
international,2.0,4.0
design,4.0,4.0
combination,1.0,3.0
rd,,3.0
represents,,3.0
degree,,3.0
pfs,8.0,3.0
spectral,,3.0
regimen,1.0,3.0
ersp,,3.0
inter-trial,,3.0
ratio,4.0,3.0
weeks,14.0,3.0
every,1.0,3.0
profile,3.0,3.0
independent,3.0,3.0
≥,4.0,3.0
prevention,1.0,3.0
individuals,2.0,3.0
previous,5.0,3.0
signals,,3.0
remained,,3.0
real-time,1.0,3.0
inhibitors,,3.0
registration,1.0,3.0
neurogenesis,,3.0
long-term,5.0,3.0
subjects,,3.0
regulation,1.0,3.0
macrophages,11.0,3.0
mirna,,3.0
via,2.0,3.0
processes,2.0,3.0
aim,5.0,3.0
oscillatory,,3.0
impairment,7.0,3.0
pathways,3.0,3.0
reducing,1.0,3.0
vessels,1.0,3.0
series,,3.0
complexes,,3.0
lateralization,,3.0
microscopy,1.0,3.0
light,1.0,3.0
action,4.0,3.0
autoimmune,,3.0
exposure,6.0,3.0
history,,3.0
namely,1.0,3.0
having,1.0,3.0
gba-carriers,,3.0
plant,,3.0
consistently,,3.0
padjusted,,3.0
neuronal,1.0,3.0
sensory,2.0,3.0
-htar,,3.0
mainly,1.0,3.0
scale,1.0,3.0
regioisomerization,,3.0
practice,,3.0
clinicaltrialsgov,1.0,3.0
less,,3.0
funding,1.0,3.0
variants,,3.0
v,,3.0
rat,,3.0
no-reflow,,3.0
taken,1.0,3.0
together,4.0,3.0
dysmenorrhea,,3.0
mg,,3.0
normalized,,3.0
provided,,3.0
additional,,3.0
tdm-induced,,3.0
synthase,,3.0
event-related,,3.0
benefit,,3.0
inhibitor,2.0,3.0
reduced,2.0,3.0
mesenteric,,3.0
taar-ko,,3.0
day,8.0,3.0
before,3.0,3.0
olfactory,,3.0
fed,,3.0
year,4.0,3.0
children,17.0,3.0
rates,2.0,3.0
resulted,1.0,3.0
arteries,,3.0
novel,,3.0
concentration,3.0,3.0
complications,2.0,3.0
estudio,,3.0
failure,1.0,3.0
society,2.0,3.0
os,13.0,3.0
into,4.0,3.0
graft-versus-host,2.0,3.0
intensity,2.0,3.0
first,8.0,3.0
complete,2.0,3.0
according,3.0,3.0
coping,,3.0
dismenorrea,,3.0
underwent,2.0,3.0
radiation,,3.0
ultrahypofractionated,,3.0
since,,3.0
body,2.0,3.0
comparing,2.0,3.0
entre,,3.0
hiv-positive,4.0,3.0
through,4.0,3.0
efficacy,8.0,3.0
pmp,,3.0
cso,,3.0
cíclico,,3.0
pacientes,,3.0
frequency,,3.0
positive,2.0,3.0
st,4.0,3.0
adapted,,3.0
statistics,,3.0
intersectional,,3.0
statistically,,3.0
o,,3.0
régimen,,3.0
organs,,3.0
access,2.0,3.0
approach,1.0,3.0
related,3.0,3.0
if,1.0,3.0
ventilatory,,3.0
consequences,1.0,3.0
continuo,,3.0
mental,3.0,3.0
cox,,3.0
lymphoblastic,2.0,3.0
sensitivity,2.0,3.0
main,2.0,3.0
factors,2.0,3.0
aerosil,,3.0
 monitoring,,3.0
onset,7.0,3.0
usa,1.0,3.0
cognitive,6.0,3.0
help,,3.0
suggest,4.0,3.0
favorable,,3.0
proposed,2.0,3.0
occurred,,3.0
ole,,3.0
policy,,3.0
late,5.0,3.0
marrow,7.0,3.0
different,5.0,3.0
aims,3.0,3.0
pathogenesis,5.0,3.0
possible,5.0,3.0
search,,3.0
genetic,3.0,3.0
markers,5.0,3.0
extension,,3.0
una,,3.0
dysfunction,4.0,3.0
cortex,1.0,3.0
change,1.0,3.0
detected,4.0,3.0
networks,,3.0
gvl,,3.0
among,3.0,3.0
complement,,3.0
act,1.0,3.0
binding,1.0,3.0
intermittent,,3.0
reported,6.0,3.0
summary,3.0,3.0
meses,,3.0
petersburg,2.0,3.0
arterial,,3.0
intermediate-risk,,3.0
pd-l,7.0,3.0
properties,3.0,3.0
representatives,,3.0
either,3.0,3.0
randomly,1.0,3.0
makers,,3.0
treated,7.0,3.0
whose,,3.0
bendamustine,,2.0
sgz,,2.0
canada,,2.0
beta-galactosidase,,2.0
monthly,,2.0
disorders,4.0,2.0
jan,,2.0
low-,,2.0
knockout,,2.0
rule,,2.0
potentially,,2.0
lesions,,2.0
induction,,2.0
cabg,,2.0
hsct,,2.0
test,2.0,2.0
interrupted,,2.0
р  ,,2.0
reasons,,2.0
svz,,2.0
upper-middle-income,,2.0
increasing,,2.0
ventricle,,2.0
solvent,,2.0
correlates,,2.0
carbene,,2.0
march,,2.0
numbers,,2.0
isomerization,,2.0
striatal,,2.0
proliferating,,2.0
time-series,,2.0
surrounding,,2.0
particular,,2.0
in-depth,,2.0
september ,,2.0
solitarius,,2.0
tractus,,2.0
located,,2.0
nephrology,,2.0
convened,,2.0
emotions,,2.0
do,,2.0
modified,,2.0
clinicians,,2.0
aao,,2.0
hemodialysis,,2.0
rationale,,2.0
barrier,,2.0
minimal,,2.0
position,,2.0
fpd,,2.0
hexsph,,2.0
macrophage,,2.0
substitution,,2.0
amino,,2.0
carrying,,2.0
post,,2.0
hoc,,2.0
mutant,,2.0
reversed,1.0,2.0
usual,,2.0
receptor,7.0,2.0
bias,,2.0
analytical,,2.0
graft,,2.0
bypass,,2.0
listening,,2.0
limitations,,2.0
costs,,2.0
atrial,,2.0
right,,2.0
pay,,2.0
copayments,,2.0
inject,,2.0
cad,,2.0
cope,,2.0
dominance,,2.0
neglect,,2.0
interhemispheric,,2.0
completely,,2.0
apparent,,2.0
hemisphere,,2.0
conduct,,2.0
rct,,2.0
generally,,2.0
indicate,1.0,2.0
single-trial,,2.0
form,,2.0
responding,,2.0
single-agent,,2.0
nrm,,2.0
endothelial,,2.0
perturbation,,2.0
induce,,2.0
synchrosqueezed,,2.0
wavelet,,2.0
components,,2.0
transform,,2.0
unfavorable,,2.0
decomposition,,2.0
μg/l,,2.0
psa,,2.0
time-frequency,,2.0
antigen,,2.0
itc,,2.0
collected,,2.0
channel,,2.0
agencies,,2.0
interaural,,2.0
decrease,1.0,2.0
trigeminal,,2.0
recorded,,2.0
sounds,,2.0
motion-onset,,2.0
investigates,,2.0
augmented,,2.0
vasodilatation,,2.0
-hydroxytryptamine,,2.0
alone,,2.0
intravital,,2.0
beam,,2.0
considered,,2.0
smi-,,2.0
currently,,2.0
hypertension,,2.0
obtain,,2.0
biological,1.0,2.0
particle,,2.0
bound,,2.0
immunoglobulin,,2.0
external,,2.0
g-positive,,2.0
fraction,,2.0
double-blind,,2.0
prespecified,,2.0
stained,,2.0
measurements,,2.0
cerebral,,2.0
cytofluorometry,,2.0
period,3.0,2.0
situ,,2.0
starved,,2.0
adjudicated,,2.0
hepatocytes,,2.0
express,,2.0
heavy-chain,,2.0
neurofilaments,,2.0
hormonal,,2.0
about,,2.0
task,,2.0
photic,,2.0
β-particle,,2.0
middle,,2.0
swell,,2.0
result,,2.0
laser-turbinectomy,,2.0
registered,,2.0
lacking,,2.0
bm,,2.0
engraftment,,2.0
dc,,2.0
terminal,,2.0
transplanted,,2.0
older,,2.0
pbsc,,2.0
prior,,2.0
none,,2.0
complication,,2.0
around,,2.0
sourced,,2.0
internet,,2.0
femoral,,2.0
relaxation,,2.0
acetylcholine-dependent,,2.0
trace,,2.0
amine-associated,,2.0
taars,,2.0
unrelated,,2.0
tolerance,,2.0
literature,,2.0
sept,,2.0
official,,2.0
mrna,9.0,2.0
liver,,2.0
procedure,,2.0
except,,2.0
out,,2.0
possibility,,2.0
addition,,2.0
substances,,2.0
histochemical,,2.0
biocompatibility,,2.0
thermometric,,2.0
peptide-,,2.0
composite,,2.0
glucagon-like,,2.0
gastrectomy,,2.0
sleeve,,2.0
measure,,2.0
interest,,2.0
contact,,2.0
ability,,2.0
regions,,2.0
ventilation,,2.0
hypoxic,,2.0
thermal,,2.0
damage,,2.0
cyclooxygenase,,2.0
statistical,,2.0
nos,,2.0
breathing,,2.0
pretreatment,,2.0
severe,,2.0
experienced,,2.0
early-stage,,2.0
spd,,2.0
those,6.0,2.0
region,1.0,2.0
benefits,1.0,2.0
total,3.0,2.0
cytokine,11.0,2.0
interpretation,1.0,2.0
women,2.0,2.0
mean,5.0,2.0
five,1.0,2.0
criteria,2.0,2.0
identify,1.0,2.0
prospective,4.0,2.0
examine,1.0,2.0
remain,2.0,2.0
adequate,1.0,2.0
las,,2.0
features,5.0,2.0
mass,1.0,2.0
subsequent,1.0,2.0
prolongado,,2.0
influence,3.0,2.0
applied,1.0,2.0
lack,1.0,2.0
marked,,2.0
slow,2.0,2.0
well-being,,2.0
developed,3.0,2.0
healthy,1.0,2.0
variable,1.0,2.0
global,3.0,2.0
manifestations,3.0,2.0
initial,4.0,2.0
relapses,2.0,2.0
observation,1.0,2.0
times,4.0,2.0
baseline,2.0,2.0
patient-reported,1.0,2.0
eligible,1.0,2.0
limited,2.0,2.0
questions,,2.0
improve,1.0,2.0
demonstrated,9.0,2.0
africa,,2.0
assessment,2.0,2.0
examined,1.0,2.0
reducción,,2.0
assess,1.0,2.0
over,1.0,2.0
severity,6.0,2.0
rearrangements,1.0,2.0
some,2.0,2.0
score,2.0,2.0
promising,1.0,2.0
asia,,2.0
contribution,2.0,2.0
intensidad,,2.0
fact,1.0,2.0
caused,1.0,2.0
presence,3.0,2.0
followed,3.0,2.0
observational,1.0,2.0
adult,3.0,2.0
diagnosed,1.0,2.0
defined,2.0,2.0
matched,2.0,2.0
maintained,1.0,2.0
días,,2.0
produced,2.0,2.0
ii-iv,1.0,2.0
ib–iiia,,2.0
mmf,1.0,2.0
affected,5.0,2.0
mujeres,,2.0
itt,,2.0
tacrolimus,1.0,2.0
immunosuppression,3.0,2.0
particularly,1.0,2.0
resultados,,2.0
sin,,2.0
immunosuppressive,1.0,2.0
orchidea,,2.0
demonstrate,1.0,2.0
conditioning,5.0,2.0
inflammation,2.0,2.0
partially,1.0,2.0
i,1.0,2.0
nucleus,1.0,2.0
schizophrenia,3.0,2.0
relevant,1.0,2.0
tested,2.0,2.0
involvement,2.0,2.0
controlled,4.0,2.0
animals,4.0,2.0
durante,,2.0
infection,5.0,2.0
seis,,2.0
nonrelapse,2.0,2.0
hazard,2.0,2.0
hr,6.0,2.0
non-small-cell,2.0,2.0
improvements,2.0,2.0
clinically,2.0,2.0
world,3.0,2.0
often,2.0,2.0
interval,2.0,2.0
confidence,2.0,2.0
descriptive,1.0,2.0
known,2.0,2.0
comprised,1.0,2.0
al,,2.0
haploidentical,4.0,2.0
russian,5.0,2.0
family,1.0,2.0
identified,3.0,2.0
improved,2.0,2.0
optimal,2.0,2.0
cycles,,2.0
post-transplantation,4.0,2.0
pronounced,3.0,2.0
cyclophosphamide,4.0,2.0
state,1.0,2.0
duration,4.0,2.0
prolongados,,2.0
living,1.0,2.0
para,,2.0
recent,2.0,2.0
another,1.0,2.0
mediated,2.0,2.0
ambos,,2.0
-day,1.0,2.0
gaucher,2.0,2.0
cohort,8.0,2.0
extent,1.0,2.0
vida,,2.0
cd,7.0,2.0
derived,1.0,2.0
causes,1.0,2.0
neurogenic,2.0,2.0
investigate,1.0,2.0
compare,1.0,2.0
stimulation,9.0,2.0
calidad,,2.0
confirmed,1.0,2.0
services,3.0,2.0
significance,1.0,2.0
physiological,,2.0
seed,,2.0
species,1.0,2.0
neuron,1.0,2.0
endothelium-dependent,1.0,2.0
reduces,1.0,2.0
fullerenes,1.0,2.0
exist,1.0,2.0
pathway,2.0,2.0
severidad,,2.0
conducted,3.0,2.0
bienestar,,2.0
characteristics,1.0,2.0
course,3.0,2.0
whether,1.0,2.0
platinum-based,,2.0
parámetros,,2.0
relacionados,,2.0
current,6.0,2.0
targeted,1.0,2.0
important,4.0,2.0
delivery,1.0,2.0
aerial,,2.0
absorption,,2.0
drug,2.0,2.0
step,2.0,2.0
peritoneal,,2.0
cause,1.0,2.0
parkinson's,4.0,2.0
resection,,2.0
greater,1.0,2.0
given,3.0,2.0
stakeholders,1.0,2.0
mejoras,,2.0
multicentre,,2.0
central,4.0,2.0
randomised,,2.0
correlations,,1.0
country-specific,,1.0
informó,,1.0
ó,,1.0
variables,,1.0
mostly,,1.0
demostraron,,1.0
alterations,,1.0
magno-,,1.0
incident,,1.0
centers,,1.0
seguridad,,1.0
participated,,1.0
bien,,1.0
severas,,1.0
adversas,,1.0
reacciones,,1.0
functioning,,1.0
neuroplasticity,,1.0
día,,1.0
neurotropic,,1.0
like,,1.0
perception,,1.0
conclusiónes,,1.0
medicación,,1.0
intervenciónes,,1.0
brain-derived,,1.0
consumer,,1.0
thirty-nine,,1.0
mid-,,1.0
veces,,1.0
parvocellular,,1.0
experimentaron,,1.0
highlights,,1.0
años,,1.0
needed,,1.0
gye,,1.0
optimise,,1.0
fractions,,1.0
immediately,,1.0
lost,,1.0
prospectively,,1.0
cincuenta,,1.0
surgical,,1.0
prostate-specific,,1.0
ns,,1.0
trescientas,,1.0
rusa,,1.0
federación,,1.0
low-risk,,1.0
hierarchically,,1.0
ginecológicas,,1.0
clínicas,,1.0
sp,,1.0
veinte,,1.0
entorno,,1.0
modes,,1.0
lamp,,1.0
marker,,1.0
colocalization,,1.0
ph,,1.0
strategies,,1.0
biomarkers,,1.0
edad,,1.0
pronunciada,,1.0
regular,,1.0
resultaron,,1.0
marcadas,,1.0
elucidation,,1.0
pencil,,1.0
pbmc-derived,,1.0
scanning,,1.0
pbs,,1.0
scans,,1.0
residue,,1.0
endpoint,,1.0
cancer--year,,1.0
materials,,1.0
vicinity,,1.0
modulated,,1.0
close,,1.0
labeling,,1.0
energy,,1.0
impt,,1.0
todos,,1.0
schedule,,1.0
estudiados,,1.0
simulations,,1.0
docking,,1.0
assessing,,1.0
un,,1.0
perfil,,1.0
resultado,,1.0
stopping,,1.0
lower-middle–income,,1.0
que,,1.0
american,,1.0
blast,,1.0
count,,1.0
sibling,,1.0
lowest,,1.0
mismatched,,1.0
marcada,,1.0
observó,,1.0
tras,,1.0
variations,,1.0
joint,,1.0
puntos,,1.0
numérica,,1.0
puntuación,,1.0
staging,,1.0
escala,,1.0
preventing,,1.0
measurable,,1.0
unusual,,1.0
collection,,1.0
principales,,1.0
desirability,,1.0
seven,,1.0
clonal,,1.0
número,,1.0
nivel,,1.0
preclinical,,1.0
significativa,,1.0
diferencia,,1.0
iiia,,1.0
cured,,1.0
union,,1.0
respectivamente,,1.0
estándar,,1.0
desviación,,1.0
medio,,1.0
internationale,,1.0
graft-versus-leukemia,,1.0
significativas,,1.0
cambio,,1.0
como,,1.0
tanto,,1.0
salvage,,1.0
antileukemic,,1.0
dismal,,1.0
immunotherapy,,1.0
contre,,1.0
le,,1.0
myelogenous,,1.0
cm,,1.0
ib,,1.0
requirieron,,1.0
ciclo,,1.0
frequent,,1.0
small-solute,,1.0
survivors,,1.0
three-year,,1.0
event-free,,1.0
limitó,,1.0
sites,,1.0
todas,,1.0
done,,1.0
ininterrumpido,,1.0
home,,1.0
augment,,1.0
salud,,1.0
crs-associated,,1.0
necessitates,,1.0
confirmó,,1.0
block,,1.0
grupos,,1.0
routine,,1.0
cannot,,1.0
menestrual,,1.0
ameliorates,,1.0
hla-matched,,1.0
weekly,,1.0
hours,,1.0
allografts,,1.0
recogida,,1.0
classic,,1.0
clearance,,1.0
pancreatitis,,1.0
analgésicos,,1.0
medidas,,1.0
fever,,1.0
income,,1.0
edition,,1.0
permuted-block,,1.0
uniform,,1.0
procedures,,1.0
tests,,1.0
suboptimal,,1.0
education,,1.0
almost,,1.0
hla-mismatched,,1.0
arteriovenous,,1.0
skin,,1.0
initiation,,1.0
vasculitis,,1.0
enterocolitis,,1.0
mucosa,,1.0
mineral,,1.0
disseminated,,1.0
intravascular,,1.0
coagulation,,1.0
datos,,1.0
disability,,1.0
transient,,1.0
observacional,,1.0
solutions,,1.0
opportunity,,1.0
anxiolytic,,1.0
antidepressant,,1.0
exert,,1.0
seedling,,1.0
antagonists,,1.0
emotional,,1.0
mgdm−,,1.0
observations,,1.0
pcna,,1.0
nuclear,,1.0
dcx,,1.0
ccf  –,,1.0
doublecortin,,1.0
neurodegenerative,,1.0
hemispheric,,1.0
indicators,,1.0
erps,,1.0
low-frequency,,1.0
antioxidant,,1.0
optimising,,1.0
hemispheres,,1.0
catabolism,,1.0
stimuli,,1.0
delayed,,1.0
read,,1.0
books,,1.0
choice,,1.0
cyclic,,1.0
estimation,,1.0
compounds,,1.0
untreated,,1.0
subgranular,,1.0
neoadjuvant,,1.0
acids,,1.0
nanocomposite,,1.0
odors,,1.0
innate,,1.0
sensing,,1.0
epithelium,,1.0
taar-taar,,1.0
decarboxylation,,1.0
globe,,1.0
products,,1.0
amines,,1.0
biogenic,,1.0
protein-coupled,,1.0
class,,1.0
modality,,1.0
responded,,1.0
limbic,,1.0
projection,,1.0
servants,,1.0
mouse,,1.0
makers/civil,,1.0
administrators/policy,,1.0
mapping,,1.0
professionals,,1.0
metabolites,,1.0
gdnf,,1.0
physicians,,1.0
indicating,,1.0
proliferation,,1.0
subventricular,,1.0
non-nephrologist,,1.0
nephrologists,,1.0
passive,,1.0
indicated,,1.0
organic,,1.0
enough,,1.0
 mg/ weeks,,1.0
time-to-event,,1.0
anti-aqp,,1.0
yield,,1.0
opposite,,1.0
astrocyte,,1.0
netto,,1.0
physiologically,,1.0
productivity,,1.0
implicated,,1.0
salad,,1.0
cascade,,1.0
tomatoes,,1.0
trigger,,1.0
stable-dose,,1.0
crop,,1.0
improving,,1.0
permitted,,1.0
carcinomas,,1.0
means,,1.0
malonate,,1.0
mitoxantrone,,1.0
primarily,,1.0
cf,,1.0
demographic,,1.0
tris-malonate,,1.0
comorbidity,,1.0
wide,,1.0
race,,1.0
historical,,1.0
regardless,,1.0
spring,,1.0
barley,,1.0
wheat,,1.0
right-hemispheric,,1.0
distributing,,1.0
trajectories,,1.0
perceived,,1.0
buspirone-dependent,,1.0
entering,,1.0
anti-aquaporin-igg-positive,,1.0
cytochemical,,1.0
moisture,,1.0
parts,,1.0
roots,,1.0
graphic,,1.0
tablet,,1.0
goal,,1.0
find,,1.0
contralateral,,1.0
aquaporin-,,1.0
diaminocarbenepdii,,1.0
capacity,,1.0
assimilation,,1.0
stronger,,1.0
contralaterality,,1.0
left,,1.0
corresponding,,1.0
delta-alpha,,1.0
attention,,1.0
vegetative,,1.0
interrelated,,1.0
motion-related,,1.0
region-specific,,1.0
germination,,1.0
for≤,,1.0
newly,,1.0
out-of-pocket,,1.0
feature,,1.0
hoffmann-la,,1.0
post-transplant,,1.0
continuos,,1.0
stain,,1.0
human’s,,1.0
f,,1.0
believed,,1.0
led,,1.0
mature,,1.0
son,,1.0
efectivos,,1.0
construction,,1.0
reducir,,1.0
offers,,1.0
non-phosphorylated,,1.0
horizontally,,1.0
oriented,,1.0
soma,,1.0
bipolar,,1.0
labeled,,1.0
layer,,1.0
cats,,1.0
dii,,1.0
well-developed,,1.0
vertical,,1.0
cíclicos,,1.0
branches,,1.0
coming,,1.0
horizontal,,1.0
visualized,,1.0
roche,,1.0
developing,,1.0
elements,,1.0
atezolizumab-related,,1.0
dos,,1.0
prospectivo,,1.0
dose-ranging,,1.0
terminology,,1.0
cohortes,,1.0
finally,,1.0
diseño,,1.0
relacionado,,1.0
follows,,1.0
gastrointestinal,,1.0
intention-to-treat,,1.0
genitourinary,,1.0
manejo,,1.0
diferentes,,1.0
patient-derived,,1.0
efectividad,,1.0
annualized,,1.0
restores,,1.0
comparar,,1.0
lymph,,1.0
objetivo,,1.0
trends,,1.0
node,,1.0
recurrences,,1.0
nine,,1.0
deaths,,1.0
comparable,,1.0
fractionation,,1.0
gi,,1.0
gu,,1.0
randomisation,,1.0
location,,1.0
suppose,,1.0
expenses,,1.0
consisted,,1.0
equivalent,,1.0
automated,,1.0
pathology,,1.0
explanations,,1.0
underpinning,,1.0
granular,,1.0
rhinitis,,1.0
carnivores,,1.0
vasomotor,,1.0
hypertrophy,,1.0
adjacent,,1.0
inter-,,1.0
intraregional,,1.0
causing,,1.0
respiration,,1.0
exchanges,,1.0
anterior,,1.0
rhinomanometry,,1.0
volumes,,1.0
exchange,,1.0
t-criterion,,1.0
average,,1.0
nose,,1.0
student's,,1.0
t-test,,1.0
genentech,,1.0
subjectively,,1.0
insufficiency,,1.0
incurred,,1.0
indicates,,1.0
airflow,,1.0
temperature,,1.0
disparities,,1.0
greatest,,1.0
rating,,1.0
share,,1.0
unmanipulated,,1.0
mediate,,1.0
reactions,,1.0
a favorable,,1.0
primates,,1.0
developmental,,1.0
corticogenesis,,1.0
decades,,1.0
quality-of-life,,1.0
analgesics,,1.0
semiconductor,,1.0
lasers,,1.0
successfully,,1.0
-point,,1.0
experiments,,1.0
rhinology,,1.0
continuously,,1.0
cycle,,1.0
barely,,1.0
menstrual,,1.0
selection,,1.0
fifty,,1.0
federation,,1.0
gynecology,,1.0
twenty,,1.0
wavelength,,1.0
endometriosis-related,,1.0
management,,1.0
cattle,,1.0
cultivation,,1.0
stasis,,1.0
monocytic,,1.0
metastases,4.0,1.0
smaller,2.0,1.0
diameter,2.0,1.0
allodynia,3.0,1.0
streptozotocin,1.0,1.0
induced,1.0,1.0
shows,1.0,1.0
weight,1.0,1.0
rr,2.0,1.0
program,1.0,1.0
searched,1.0,1.0
targeting,1.0,1.0
risks,1.0,1.0
measurement,2.0,1.0
whom,1.0,1.0
participate,2.0,1.0
inclusion,1.0,1.0
published,1.0,1.0
crd,1.0,1.0
pattern,1.0,1.0
auditory,4.0,1.0
aged,2.0,1.0
divided,2.0,1.0
tissue,5.0,1.0
acetylcholine,1.0,1.0
doses,1.0,1.0
acid,6.0,1.0
experiment,1.0,1.0
health-related,1.0,1.0
january,1.0,1.0
cutoff,1.0,1.0
secondary,1.0,1.0
investigator-assessed,2.0,1.0
stable,1.0,1.0
asymptomatic,1.0,1.0
kinase,1.0,1.0
caution,1.0,1.0
require,1.0,1.0
noted,1.0,1.0
tone,1.0,1.0
usage,1.0,1.0
gaps,1.0,1.0
membrane,1.0,1.0
bodies,1.0,1.0
required,2.0,1.0
experience,1.0,1.0
elevated,1.0,1.0
assessed,7.0,1.0
protein-,1.0,1.0
necrosis,1.0,1.0
tumor,2.0,1.0
plasma,13.0,1.0
administered,2.0,1.0
knowledge,1.0,1.0
start,2.0,1.0
busulfan,1.0,1.0
fludarabine,1.0,1.0
containing,1.0,1.0
mofetil,1.0,1.0
mycophenolate,1.0,1.0
schedules,1.0,1.0
target,1.0,1.0
mg/kg,4.0,1.0
then,2.0,1.0
numerical,1.0,1.0
profiles,2.0,1.0
growth,1.0,1.0
participating,1.0,1.0
biochemical,2.0,1.0
established,1.0,1.0
excluded,2.0,1.0
increases,2.0,1.0
trend,1.0,1.0
females,1.0,1.0
computed,2.0,1.0
abnormal,1.0,1.0
deviation,1.0,1.0
sex,3.0,1.0
explored,1.0,1.0
recruited,2.0,1.0
decision,1.0,1.0
committee,1.0,1.0
consistent,2.0,1.0
component,1.0,1.0
motor,7.0,1.0
suggesting,1.0,1.0
disequilibrium,,1.0
noxious,,1.0
urethane-anesthetized,,1.0
-htars,,1.0
ibs,,1.0
useful,,1.0
modifier,,1.0
variant,,1.0
tt,,1.0
linkage,,1.0
release,1.0,1.0
mutation,,1.0
pd-gba,,1.0
genotyped,,1.0
genome-wide,,1.0
limp-,,1.0
integral,,1.0
genetics,1.0,1.0
part,1.0,1.0
colorectal,,1.0
distension,,1.0
sustained,,1.0
– mg kg−,,1.0
mirnas,,1.0
microrna,,1.0
pronociceptive,,1.0
anti-,,1.0
dependents,,1.0
-hta,,1.0
supraspinal,,1.0
way,,1.0
intra-cerebroventricular,,1.0
blocked,,1.0
crd-evoked,,1.0
attenuates,,1.0
inverts,,1.0
inhibits,,1.0
crd-induced,,1.0
dose-depended,,1.0
time-,,1.0
major,1.0,1.0
daily,1.0,1.0
spinal,6.0,1.0
attenuated,1.0,1.0
parkinsonism,2.0,1.0
combined,1.0,1.0
perform,1.0,1.0
morphology,2.0,1.0
terms,1.0,1.0
content,1.0,1.0
extracellular,2.0,1.0
local,1.0,1.0
safe,1.0,1.0
dynamics,1.0,1.0
respond,1.0,1.0
basal,2.0,1.0
production,8.0,1.0
unclear,1.0,1.0
residual,1.0,1.0
modulation,1.0,1.0
animal,1.0,1.0
injury,3.0,1.0
encoded,1.0,1.0
functions,2.0,1.0
pd-related,1.0,1.0
relationship,1.0,1.0
affects,1.0,1.0
neurophysiological,1.0,1.0
does,1.0,1.0
firing,1.0,1.0
iv,2.0,1.0
anaesthetised,1.0,1.0
trigeminocervical,1.0,1.0
recordings,1.0,1.0
electrophysiological,1.0,1.0
advantage,1.0,1.0
widely,1.0,1.0
channels,1.0,1.0
suppression,3.0,1.0
mechanism,6.0,1.0
solve,1.0,1.0
antinociceptive,3.0,1.0
forms,1.0,1.0
contribute,3.0,1.0
bind,1.0,1.0
cultured,,1.0
oxygen,1.0,1.0
water-soluble,2.0,1.0
remains,1.0,1.0
derivatives,1.0,1.0
functionalisation,1.0,1.0
research,9.0,1.0
therefore,2.0,1.0
bacteria,1.0,1.0
ros,6.0,1.0
reactive,1.0,1.0
pcr,1.0,1.0
biomedicine,1.0,1.0
fields,1.0,1.0
application,2.0,1.0
c,1.0,1.0
expanded,1.0,1.0
several,1.0,1.0
relatively,1.0,1.0
allowing,1.0,1.0
hsa,1.0,1.0
line,2.0,1.0
haemolysis,1.0,1.0
platelet,1.0,1.0
blasts,1.0,1.0
while,5.0,1.0
general,2.0,1.0
majority,2.0,1.0
progression,8.0,1.0
relapse-free,3.0,1.0
following,2.0,1.0
detect,1.0,1.0
able,2.0,1.0
center,1.0,1.0
syndrome,3.0,1.0
single-center,1.0,1.0
dynamic,3.0,1.0
pbmc,1.0,1.0
peripheral,6.0,1.0
genotoxicity,1.0,1.0
aggregation,1.0,1.0
believe,1.0,1.0
standard,3.0,1.0
heterogeneity,1.0,1.0
exhibited,2.0,1.0
inflammatory,5.0,1.0
understood,1.0,1.0
death,3.0,1.0
underlying,4.0,1.0
nervous,1.0,1.0
accompanied,3.0,1.0
behavioral,2.0,1.0
water,1.0,1.0
chain,1.0,1.0
slightly,1.0,1.0
polymerase,1.0,1.0
substantial,1.0,1.0
administration,4.0,1.0
investigated,2.0,1.0
affect,4.0,1.0
life,4.0,1.0
role,6.0,1.0
childhood,1.0,1.0
leads,1.0,1.0
members,3.0,1.0
great,2.0,1.0
many,5.0,1.0
viruses,3.0,1.0
establish,1.0,1.0
antibodies,2.0,1.0
approximately,2.0,1.0
creation,1.0,1.0
antibody,6.0,1.0
devoted,2.0,1.0
work,3.0,1.0
differential,3.0,1.0
others,1.0,1.0
upper,4.0,1.0
tract,4.0,1.0
died,1.0,1.0
reveal,2.0,1.0
sources,3.0,1.0
diseases,2.0,1.0
any,5.0,1.0
preliminary,2.0,1.0
approaches,1.0,1.0
ii,3.0,1.0
hematopoietic,2.0,1.0
comparative,4.0,1.0
heart,1.0,1.0
myeloablative,1.0,1.0
limitation,1.0,1.0
when,2.0,1.0
remission,1.0,1.0
adults,1.0,1.0
hct,2.0,1.0
allogeneic,1.0,1.0
report,3.0,1.0
recommended,2.0,1.0
slowly,1.0,1.0
occurs,1.0,1.0
process,1.0,1.0
depending,1.0,1.0
condition,1.0,1.0
yet,1.0,1.0
characteristic,1.0,1.0
effectiveness,1.0,1.0
describes,1.0,1.0
studying,1.0,1.0
partial,2.0,1.0
postnatal,1.0,1.0
 mg/kg,2.0,1.0
techniques,1.0,1.0
deficits,1.0,1.0
symptoms,4.0,1.0
they,4.0,1.0
experimental,1.0,1.0
staining,2.0,1.0
up,3.0,1.0
mixture,1.0,1.0
samples,2.0,1.0
here,8.0,1.0
month,1.0,1.0
and/or,2.0,1.0
hundred,1.0,1.0
recruiting,1.0,1.0
replacement,1.0,1.0
typical,1.0,1.0
case,4.0,1.0
disruption,1.0,1.0
paper,2.0,1.0
described,2.0,1.0
pediatric,1.0,1.0
populations,2.0,1.0
social,1.0,1.0
stages,5.0,1.0
ongoing,2.0,1.0
clinics,1.0,1.0
provides,1.0,1.0
direct,1.0,1.0
japan,2.0,1.0
addressing,3.0,1.0
importance,3.0,1.0
future,4.0,1.0
need,4.0,1.0
parallel,1.0,1.0
how,2.0,1.0
systematic,4.0,1.0
allowed,1.0,1.0
evident,1.0,1.0
determine,2.0,1.0
prognosis,2.0,1.0
multiple,8.0,1.0
germany,2.0,1.0
oct,4.0,1.0
optical,1.0,1.0
testing,2.0,1.0
male,2.0,1.0
propose,1.0,1.0
analyze,2.0,1.0
purpose,1.0,1.0
support,1.0,1.0
collectively,1.0,1.0
value,1.0,1.0
correlated,3.0,1.0
furthermore,2.0,1.0
carriers,2.0,1.0
g,5.0,1.0
along,2.0,1.0
distinct,1.0,1.0
   years,,1.0
men,,1.0
-a,,1.0
rebreathing,,1.0
post-transplantation-cyclophosphamide,,1.0
hla-haploidentical,,1.0
underlies,,1.0
mediates,,1.0
cross-talk,,1.0
nos-related,,1.0
hypoxia,,1.0
normoxia,,1.0
nonspecific,,1.0
carotid,,1.0
l-name,,1.0
ester,,1.0
methyl,,1.0
arginine,,1.0
l-ng-nitro,,1.0
diclofenac,,1.0
modulate,,1.0
circulating,,1.0
feasible,,1.0
malignancies,,1.0
day-,,1.0
multivariable,,1.0
came,,1.0
public,,1.0
attempt,,1.0
broadening,,1.0
translated,,1.0
equivalents,,1.0
government-run,,1.0
police,,1.0
ministries,,1.0
countries’,,1.0
websites,,1.0
nov,,1.0
recourse,,1.0
manifest,,1.0
extreme,,1.0
concerns,,1.0
profound,,1.0
hypothesised,,1.0
theranostics,,1.0
searches,,1.0
dilation,,1.0
silica,,1.0
underlie,,1.0
favour,,1.0
mechanosensitive,,1.0
selective,,1.0
afferents,,1.0
innervated,,1.0
meningeal,,1.0
contributed,,1.0
immobilisation,,1.0
facilitated,,1.0
differently,,1.0
directly,,1.0
centre,,1.0
relay,,1.0
took,,1.0
ganglion,,1.0
ion,,1.0
silicon,,1.0
dioxide,,1.0
amorphous,,1.0
varying,,1.0
inactivation,,1.0
inhibition,,1.0
applications,,1.0
nanomaterial,,1.0
antiradical,,1.0
cyto-,,1.0
photoinduced,,1.0
spontaneous,,1.0
biologically,,1.0
composites,,1.0
allows,,1.0
silicas,,1.0
silanol,,1.0
sorption,,1.0
physicochemical,,1.0
volume,,1.0
pore,,1.0
government,,1.0
restricted,,1.0
referred,,1.0
stigma-related,,1.0
confront,,1.0
settings,,1.0
formal,,1.0
outside,,1.0
scores,,1.0
satisfaction,,1.0
experiences,,1.0
expectations,,1.0
handle,,1.0
acceptance,,1.0
flexibility,,1.0
psychological,,1.0
format,,1.0
sessions,,1.0
harm,,1.0
delivering,,1.0
organizations,,1.0
civil,,1.0
negativities,,1.0
lives,,1.0
originating,,1.0
stigma's,,1.0
confocal,,1.0
lysosomes,,1.0
spectrometry,,1.0
tandem,,1.0
coupled,,1.0
chromatography,,1.0
liquid,,1.0
spots,,1.0
dried,,1.0
hexosylsphingosine,,1.0
thirty,,1.0
fourteen,,1.0
chaperones,,1.0
pharmacological,,1.0
parkinson,,1.0
commonly,,1.0
encoding,,1.0
commitment,,1.0
community-based,,1.0
residents,,1.0
wales,,1.0
korea,,1.0
zealand,,1.0
leipzig,,1.0
chile,,1.0
columbia,,1.0
british,,1.0
alberta,,1.0
australia,,1.0
began,,1.0
script,,1.0
cis,,1.0
rrs,,1.0
ratios,,1.0
ten,,1.0
whole-country,,1.0
april,,1.0
relaxed,,1.0
pragmatic,,1.0
california,,1.0
illinois,,1.0
cook,,1.0
county,,1.0
treatment’,,1.0
‘stigma,,1.0
utilization,,1.0
unfold,,1.0
economic,,1.0
longer-term,,1.0
situation,,1.0
poised,,1.0
vigilant,,1.0
pre-pandemic,,1.0
declined,,1.0
unchanged,,1.0
largely,,1.0
context,,1.0
ecuador,,1.0
counties,,1.0
texas,,1.0
unknown,,1.0
attack,,1.0
mechanotransduction,,1.0
diet,,1.0
serotonin,,1.0
arterioles,,1.0
third-order,,1.0
contraction,,1.0
dose-dependent,,1.0
injection,,1.0
single,,1.0
 weeks,,1.0
high-fat,,1.0
bond,,1.0
wistar,,1.0
bed,,1.0
greatly,,1.0
morphological,,1.0
imbalance,,1.0
endothelium-derived,,1.0
top,,1.0
ranks,,1.0
phenylephrine,,1.0
guanylate,,1.0
cyclase,,1.0
tendency,,1.0
comparisons,,1.0
reached,,1.0
remaining,,1.0
strikingly,,1.0
users,,1.0
no-adverse-events,,1.0
approached,,1.0
responsive,,1.0
compassionate,,1.0
tyrosine,,1.0
non-small,,1.0
few,,1.0
potent,,1.0
allow,,1.0
conjunction,,1.0
endothelin-,,1.0
bioavailable,,1.0
fragment,,1.0
carbon–nitrogen,,1.0
hyperalgesia,,1.0
unit,,1.0
pdii,,1.0
atherosclerosis,,1.0
strongly,,1.0
corresponds,,1.0
non-cad,,1.0
five-fold,,1.0
multivessel,,1.0
tree,,1.0
relative,,1.0
breaking,,1.0
myocardium,,1.0
vessel,,1.0
r  ,,1.0
syntax,,1.0
correlation,,1.0
valve,,1.0
scheduled,,1.0
elective,,1.0
synthesized,,1.0
cis-pdclcnxyl,,1.0
benzo--thiazol--amines,,1.0
structurally,,1.0
rate-determining,,1.0
spectrometric,,1.0
kinetic,,1.0
interchange/dissociative,,1.0
strength,,1.0
accelerate,,1.0
polarity,,1.0
moiety,,1.0
benzothiazole,,1.0
substituents,,1.0
electron-withdrawing,,1.0
hammett,,1.0
intramolecularly,,1.0
first-order,,1.0
diaminocarbene,,1.0
interconvert,,1.0
regioisomers,,1.0
regard,,1.0
excellent,,1.0
must,,1.0
speed,,1.0
predicts,,1.0
sf,,1.0
internal,,1.0
lf,,1.0
labile,,1.0
quickly,,1.0
reagent,,1.0
schiff's,,1.0
β-particles,,1.0
experiencing,,1.0
poorly,,1.0
nm,,1.0
glycogenin,,1.0
concentric,,1.0
shape,,1.0
spherical,,1.0
full,,1.0
thought,,1.0
tier,,1.0
never,,1.0
amount,,1.0
makes,,1.0
mechanical,,1.0
sensitisation,,1.0
origin,,1.0
excitation,,1.0
shift,,1.0
bioelectric,,1.0
photostimulation,,1.0
manifested,,1.0
instantaneous,,1.0
identifiers,,1.0
benefit–risk,,1.0
nasopharyngitis,,1.0
headache,,1.0
completed,,1.0
 mg/,,1.0
intravenous,,1.0
anti-aquaporin-,,1.0
indicator,,1.0
resetting,,1.0
generated,,1.0
infarct-limiting,,1.0
enhanced,,1.0
surgeries,,1.0
compensation,,1.0
reductions,,1.0
myography,,1.0
wire,,1.0
infections,5.0,1.0
determination,,1.0
ischemia-reperfusion,,1.0
subjected,,1.0
insulin,,1.0
gastric,,1.0
roux-en-y,,1.0
transposition,,1.0
ileal,,1.0
sham-operated,,1.0
phenomenon,,1.0
contractile,,1.0
contractility,,1.0
consistency,,1.0
beneficial,,1.0
theta-alpha,,1.0
displacement,,1.0
abrupt,,1.0
conversely,,1.0
non-coherent,,1.0
gradual,,1.0
highest,,1.0
delta-to-alpha,,1.0
cp,,1.0
cn,,1.0
magnitude,,1.0
similarly,,1.0
calculated,,1.0
stationary,,1.0
velocities,,1.0
moving,,1.0
cardiovascular,,1.0
feline,,1.0
play,2.0,
essential,4.0,
psycho-emotional,1.0,
impairments,2.0,
functional,4.0,
nmda,3.0,
ampa,3.0,
glutamate,3.0,
bacterial,3.0,
critical,3.0,
synapse,2.0,
maturation,2.0,
subunit,2.0,
composition,2.0,
repetitive,1.0,
lipopolysaccharide,1.0,
lps,1.0,
intraperitoneal,1.0,
ip,1.0,
 μg/kg/day,1.0,
Unnamed: 61,315.0,
mimicking,2.0,
infectious,2.0,
subunits,1.0,
young,3.0,
glunb,1.0,
hippocampus,8.0,
western,2.0,
blot,2.0,
assay,3.0,
glun,1.0,
gluna,1.0,
glua,1.0,
lps-treated,1.0,
exploratory,2.0,
locomotor,1.0,
open,2.0,
field,1.0,
learning,1.0,
morris,1.0,
maze,1.0,
hippocampal,1.0,
synaptic,2.0,
potentiation,3.0,
lps-treatment,1.0,
alters,2.0,
ionotropic,2.0,
disturbs,1.0,
plasticity,2.0,
behavior,1.0,
manganese,2.0,
mn,4.0,
lead,3.0,
toxic,1.0,
cns,2.0,
undoubtedly,1.0,
involve,1.0,
explore,1.0,
long-lasting,2.0,
intranasal,4.0,
focusing,1.0,
catecholamine,1.0,
norepinephrine,2.0,
striatum,5.0,
instillation,1.0,
mncl,2.0,
solution,2.0,
once,1.0,
impaired,3.0,
movement,1.0,
gait,1.0,
dopac,2.0,
simultaneously,1.0,
assayed,1.0,
cytokines,6.0,
il-β,1.0,
iba-,1.0,
nfκb,1.0,
dramatic,1.0,
ikb,1.0,
induces,2.0,
neuroinﬂammation,2.0,
neurotransmission,1.0,
disturbance,2.0,
shortly,1.0,
syphilis,2.0,
appeared,2.0,
europe,1.0,
columbus’,1.0,
voyage,1.0,
big,1.0,
pox,1.0,
became,1.0,
issue,1.0,
diagnosis,6.0,
royal,1.0,
made,3.0,
aware,2.0,
adolescence,1.0,
onward,1.0,
czar,1.0,
peter,4.0,
contacts,1.0,
contracted,2.0,
sexually,2.0,
transmitted,2.0,
stds,1.0,
quite,1.0,
his,2.0,
era,2.0,
nevertheless,1.0,
contributions,2.0,
contemporary,1.0,
doctors,1.0,
later,2.0,
medical,1.0,
he,2.0,
std,1.0,
likely,3.0,
renal,1.0,
urinary,1.0,
obstruction,1.0,
world's,1.0,
etiologic,1.0,
agents,2.0,
behind,1.0,
urtis,1.0,
diverse,2.0,
set,1.0,
pathogens,7.0,
influenza,6.0,
parainfluenza,1.0,
adenovirus,1.0,
rhinovirus,1.0,
viral,5.0,
sometimes,1.0,
complicated,1.0,
diversity,1.0,
similarity,1.0,
presentation,1.0,
enables,1.0,
simultaneous,2.0,
detection,2.0,
urti,1.0,
iav,2.0,
ibv,1.0,
rsv,1.0,
hadv,1.0,
hpiv,2.0,
microarray,4.0,
technology,2.0,
utilized,1.0,
accomplish,1.0,
preparation,2.0,
protein,8.0,
microchip,4.0,
selected,2.0,
monoclonal,3.0,
aforementioned,1.0,
pair,1.0,
created,1.0,
core,1.0,
working,3.0,
conditions,3.0,
optimized,1.0,
balance,3.0,
convenience,1.0,
maximal,1.0,
mind,2.0,
one-step,1.0,
accomplishing,1.0,
elisa-like,1.0,
sandwich,1.0,
interaction,1.0,
manufactured,1.0,
reference,6.0,
strains,1.0,
limits,4.0,
lod,3.0,
 ng/ml,2.0,
ranged,1.0,
better,2.0,
elisa,2.0,
inferior,1.0,
good,2.0,
alternative,1.0,
existing,1.0,
quick,1.0,
overnight,1.0,
inexpensive,1.0,
screening,2.0,
conducive,1.0,
panel,1.0,
include,2.0,
scavenging,2.0,
inhibiting,1.0,
inactivating,1.0,
elaboration,1.0,
diagnostic,4.0,
tools,1.0,
hydrophobicity,1.0,
impedes,1.0,
practical,1.0,
actuality,1.0,
leading,3.0,
amphiphilic,1.0,
derivative,2.0,
extensive,1.0,
biomedical,2.0,
investigation,1.0,
compound,1.0,
human,7.0,
albumin,1.0,
radical,2.0,
diphenylpicrylhydrazyl,1.0,
dpph,1.0,
photodynamic,1.0,
cytotoxicity,1.0,
embryonic,1.0,
hek,1.0,
erythrocytes',1.0,
mononuclear,1.0,
moreover,2.0,
structural,2.0,
cccooh–ho,1.0,
binary,1.0,
md,1.0,
distribution,2.0,
associates,1.0,
retrospective,3.0,
checkpoint,6.0,
biopsies,2.0,
myelodysplastic,2.0,
mds,3.0,
consecutive,2.0,
antigens,1.0,
pd-,2.0,
lag-,1.0,
gal-,2.0,
tim-,3.0,
time-to-progression,1.0,
intensive,1.0,
cases,7.0,
seen,1.0,
ctla,1.0,
ligands,2.0,
co-expressed,1.0,
ligand,2.0,
progressed,1.0,
tim,1.0,
ipss,1.0,
ipss-r,1.0,
scales,4.0,
underlined,1.0,
heterogeneous,1.0,
immune,9.0,
warrants,1.0,
define,1.0,
develop,3.0,
broadly,1.0,
disrupted,1.0,
non-invasive,1.0,
nibs,10.0,
rapid,3.0,
societal,1.0,
evolving,1.0,
regulatory,4.0,
restrictions,2.0,
planning,1.0,
continue,1.0,
throughout,1.0,
restarted,1.0,
abated,1.0,
urgency,1.0,
neurological,3.0,
indications,1.0,
catalyst,1.0,
fundamental,1.0,
dampened,1.0,
efforts,1.0,
address,2.0,
life-threatening,1.0,
aspects,2.0,
rather,1.0,
heightened,1.0,
mitigate,1.0,
facilitate,1.0,
re-establishment,1.0,
operations,3.0,
outbreaks,1.0,
discuss,3.0,
framework,1.0,
balancing,1.0,
considerations,4.0,
needs,1.0,
focus,2.0,
transcranial,4.0,
magnetic,2.0,
tms,1.0,
electrical,3.0,
tes,1.0,
tdcs,1.0,
alternating,1.0,
tacs,1.0,
consensus,1.0,
guidelines,2.0,
practices,2.0,
managing,2.0,
reopening,1.0,
laboratories,1.0,
immediate,1.0,
document,1.0,
reflects,1.0,
experts,1.0,
domain-relevant,1.0,
expertise,1.0,
spanning,2.0,
basic,2.0,
perspective,1.0,
outline,1.0,
resources,1.0,
optimization,1.0,
accommodations,1.0,
demographics,1.0,
phases,1.0,
-step,1.0,
checklist,1.0,
removing,1.0,
streamlining,1.0,
in-person,1.0,
protocols,1.0,
incorporating,1.0,
telemedicine,1.0,
covid--associated,1.0,
recommendations,1.0,
implementing,1.0,
distancing,1.0,
sterilization,1.0,
equipment,1.0,
comorbidities,1.0,
regarding,3.0,
resource,1.0,
outlined,1.0,
specifically,1.0,
sub-populations,1.0,
stroke,1.0,
addiction,1.0,
elderly,1.0,
numerous,2.0,
case-examples,1.0,
urgent,1.0,
maintain,1.0,
anticipating,1.0,
waves,1.0,
robust,1.0,
structured,1.0,
strategy,1.0,
anticipated,1.0,
challenges,1.0,
maintaining,1.0,
scientific,2.0,
rigor,1.0,
sclerosis,4.0,
ms,5.0,
still,2.0,
galanin,3.0,
polymorphism,5.0,
earlier,3.0,
objectives,4.0,
confirm,1.0,
previously,1.0,
candidates,1.0,
stratification,1.0,
msss,2.0,
armss,1.0,
pi,1.0,
minor,4.0,
allele,4.0,
confirming,1.0,
proportion,1.0,
msss  ,1.0,
genotypes,1.0,
ag,1.0,
gg,1.0,
aa,1.0,
genotype,1.0,
describe,1.0,
recurrent,4.0,
idiopathic,4.0,
exudative,2.0,
polymorphous,2.0,
vitelliform,3.0,
maculopathy,2.0,
aepvm,5.0,
detail,1.0,
algorithm,2.0,
-month,1.0,
eight,1.0,
review,7.0,
charts,1.0,
multimodal,2.0,
imaging,3.0,
electrophysiology,2.0,
repeatedly,1.0,
ophthalmic,1.0,
examinations,3.0,
best-corrected,1.0,
acuity,1.0,
bcva,1.0,
slit-lamp,1.0,
fundus,5.0,
digital,1.0,
photography,1.0,
time-domain,1.0,
tomography,2.0,
stratus,1.0,
carl,1.0,
zeiss,1.0,
meditec,1.0,
spectral-domain,1.0,
spectralis-oct,1.0,
heidelberg,2.0,
engineering,2.0,
autofluorescence,3.0,
faf,1.0,
fluorescein,1.0,
angiography,2.0,
fa,2.0,
indocyanine,1.0,
green,1.0,
icga,1.0,
hra,1.0,
microperimetry,1.0,
mp-,1.0,
microperimeter,1.0,
nidek,1.0,
flare,1.0,
photometry,1.0,
kowa,1.0,
fm-,1.0,
rare,1.0,
-year-old,1.0,
caucasian,2.0,
serous,2.0,
neuroepithelial,1.0,
detachment,1.0,
irregular,1.0,
retinal,4.0,
elevations,2.0,
ophthalmoscopically,1.0,
resembling,1.0,
folds,2.0,
subretinal,1.0,
accumulation,2.0,
yellow–white,1.0,
deposits,1.0,
rarely,1.0,
even,3.0,
indocyanine-,1.0,
fluorescein-negative,1.0,
intraretinal,1.0,
cystic,1.0,
optic,1.0,
disc,1.0,
hyperfluorescence,1.0,
choroidal,1.0,
thickness,1.0,
recovery,4.0,
very,5.0,
anatomical,1.0,
improvement,2.0,
bimonthly,2.0,
evaluation,4.0,
sd-oct,2.0,
informative,1.0,
demonstrating,1.0,
evolution,1.0,
pathological,1.0,
signs,1.0,
uncertain,1.0,
presentations,1.0,
pathologic,1.0,
overlap,1.0,
should,4.0,
high-risk,1.0,
t,2.0,
t-all,2.0,
hla-identical,1.0,
haplo-,1.0,
becoming,1.0,
donation,1.0,
scarce,1.0,
predictive,2.0,
female,1.0,
ptcy,8.0,
incidences,1.0,
leukemia-free,2.0,
lfs,8.0,
grfs,1.0,
highly,3.0,
influenced,2.0,
being,1.0,
second,6.0,
multivariate,2.0,
negatively,2.0,
whereas,4.0,
encouraging,1.0,
challenging,1.0,
despite,3.0,
small,2.0,
sample,1.0,
calling,1.0,
question,1.0,
irradiation-based,1.0,
heavy,5.0,
drinking,4.0,
smoking,8.0,
pro-inflammatory,1.0,
chd,3.0,
alcohol,8.0,
varenicline,4.0,
cytisine,4.0,
proven,2.0,
therapies,2.0,
cessation,2.0,
consumption,3.0,
nor,2.0,
protocol,3.0,
agonists,1.0,
ethanol,1.0,
tobacco,3.0,
elimination,1.0,
russians,1.0,
four-arm,1.0,
parallel-group,1.0,
nicotine,1.0,
nrt,3.0,
smokers,3.0,
interested,1.0,
cutting,1.0,
down,1.0,
varenicline  nrt,1.0,
placebo  active,2.0,
cytisine  nrt,1.0,
evidence-based,1.0,
counseling,1.0,
medication,2.0,
past,1.0,
craving,1.0,
cigarettes,1.0,
point,2.0,
prevalence,1.0,
abstinence,1.0,
addresses,1.0,
paucity,1.0,
guide,1.0,
mast,4.0,
a/hn,2.0,
virus,2.0,
immunized,3.0,
cba,1.0,
intramuscularly,1.0,
formalin-inactivated,1.0,
a/vietnam//,1.0,
hnnibrg-,1.0,
hn,2.0,
immunization,1.0,
infected,1.0,
intranasally,1.0,
a/indonesia//,1.0,
hnidcdc-rg,1.0,
half,1.0,
antihistamines,2.0,
vaccinated,1.0,
protected,1.0,
lethality,1.0,
pbs-immunized,1.0,
immunohistochemical,1.0,
examination,4.0,
lungs,2.0,
larger,1.0,
quantity,1.0,
activated,1.0,
mock-immunized,1.0,
histamine,3.0,
produce,1.0,
incomplete,1.0,
formation,1.0,
vaccination,1.0,
mismatch,1.0,
vaccine,1.0,
gestational,10.0,
methylazoxymethanol,1.0,
acetate,1.0,
mam,6.0,
produces,1.0,
offspring,1.0,
phenotype,4.0,
positive-,1.0,
negative-like,1.0,
dopaminergic,1.0,
abnormalities,2.0,
show,2.0,
prenatally,1.0,
display,1.0,
d,15.0,
prefrontal,1.0,
pfc,2.0,
accumbens,1.0,
exclusively,1.0,
perfusion,1.0,
circle,1.0,
willis,1.0,
paralleled,1.0,
enlargement,1.0,
lateral,1.0,
ventricles,1.0,
resonance,1.0,
mri,2.0,
peripubertal,2.0,
non-euphoric,1.0,
phytocannabinoid,1.0,
cannabidiol,5.0,
pnd,2.0,
reverse,1.0,
exposed,2.0,
up-regulation,1.0,
prevented,1.0,
haloperidol,1.0,
 mg/kg/day,1.0,
regional,1.0,
flow,7.0,
modelling,1.0,
predicted,1.0,
preferentially,1.0,
where,1.0,
conformation,1.0,
ionic-lock,1.0,
conserved,1.0,
gpcrs,1.0,
altered,4.0,
transcript,1.0,
might,1.0,
represent,1.0,
unexplored,1.0,
antipsychotic,1.0,
timing,3.0,
transplant,1.0,
haplo-hsct,3.0,
standardized,3.0,
cyclosporine,1.0,
csa,1.0,
csa  mmf,2.0,
younger,1.0,
thiotepa,1.0,
refined,1.0,
rgrfs,3.0,
improves,2.0,
pivotal,1.0,
synucleinopathy,2.0,
parkinson’s,2.0,
neurotoxic,1.0,
alpha-synuclein,1.0,
dementia,7.0,
lewy,1.0,
dlb,6.0,
estimate,3.0,
synucleinopathies,3.0,
pdd,6.0,
interferon-gamma,1.0,
ifn-gamma,2.0,
interleukin,1.0,
il-,16.0,
alpha,1.0,
tnf-alpha,3.0,
monocyte,1.0,
chemoattractant,1.0,
mcp-,2.0,
luminex,1.0,
array,2.0,
mini–mental,1.0,
mmse,1.0,
demetia,1.0,
metastatic,2.0,
mnsclc,3.0,
first-,1.0,
second-line,1.0,
options,1.0,
arctic,3.0,
iii,1.0,
durvalumab,11.0,
tremelimumab,9.0,
soc,12.0,
third-line,2.0,
sub-studies,1.0,
tcs,1.0,
expressing,1.0,
programmed,1.0,
ligand-,1.0,
qw,6.0,
b,4.0,
tc,3.0,
 ,1.0,
durvalumab ,5.0,
mg/kg ,1.0,
end,4.0,
points,3.0,
progression-free,2.0,
p ,2.0,
treatment-related,1.0,
heavily,1.0,
pretreated,1.0,
meaningful,2.0,
identifier,1.0,
because,3.0,
intervals,4.0,
ris,7.0,
biochemistry,2.0,
analytes,7.0,
joined,1.0,
values,4.0,
rvs,6.0,
coordinated,1.0,
ifcc,2.0,
c-ridl,2.0,
harmonized,1.0,
volunteers,2.0,
saint-petersburg,1.0,
moscow,1.0,
yekaterinburg,1.0,
variation,2.0,
regression,2.0,
partitioning,1.0,
judged,1.0,
anova,1.0,
latent,1.0,
exclusion,1.0,
lave,2.0,
metabolic,2.0,
inappropriate,1.0,
sampling,2.0,
parametric,1.0,
appreciable,1.0,
between-city,1.0,
partition,1.0,
age-related,1.0,
especially,2.0,
exaggerated,1.0,
nutritional,2.0,
closely,1.0,
bmi,3.0,
prominently,1.0,
bmi   kg/m,1.0,
determining,1.0,
age-specific,2.0,
lowering,1.0,
up-to-date,1.0,
detailed,1.0,
consideration,2.0,
transplacental,1.0,
passage,1.0,
maternal,11.0,
thyroid,11.0,
hormone,2.0,
normal,6.0,
fetal,3.0,
overt,1.0,
hypothyroidism,4.0,
hyperthyroidism,1.0,
birthweight,12.0,
subclinical,4.0,
birthweight—both,1.0,
third,3.0,
trimester,3.0,
pregnancy,6.0,
associations,1.0,
individual-participant,3.0,
meta-analysis,2.0,
medline,1.0,
ovid,1.0,
embase,1.0,
web,1.0,
science,1.0,
cochrane,1.0,
register,2.0,
trials,1.0,
google,1.0,
scholar,1.0,
inception,1.0,
issued,1.0,
invitations,1.0,
authors,2.0,
join,1.0,
consortium,1.0,
pregnancies,2.0,
in-vitro,1.0,
fertilisation,1.0,
pre-existing,1.0,
miscarriages,1.0,
stillbirths,1.0,
sga,5.0,
neonates,2.0,
newborn,1.0,
analysed,1.0,
mixed-effects,1.0,
models,3.0,
adjusting,1.0,
ethnicity,1.0,
parity,1.0,
birth,3.0,
pre-registered,1.0,
reviews,1.0,
reports,2.0,
cohorts,3.0,
met,1.0,
agreed,1.0,
unpublished,1.0,
datasets,1.0,
added,2.0,
giving,1.0,
 ,1.0,
mother–child,1.0,
pairs,1.0,
exclusions,1.0,
stimulating,1.0,
tsh,4.0,
thyroxine,1.0,
ft,4.0,
isolated,5.0,
hypothyroxinaemia,3.0,
euthyroidism,2.0,
adjusted,2.0,
odds,1.0,
−,8.0,
sd,2.0,
estimates,1.0,
peroxidase,1.0,
pinteraction,1.0,
inverse,1.0,
dose-response,1.0,
advance,1.0,
understanding,4.0,
relationships,1.0,
prompt,1.0,
careful,1.0,
levothyroxine,1.0,
netherlands,1.0,
organization,1.0,
grant,1.0,
third-generation,1.0,
tyrosine-kinases,1.0,
tki,1.0,
alk/ros,3.0,
fusions,1.0,
fda,1.0,
approved,1.0,
tki-pretreated,1.0,
approval,1.0,
pending,1.0,
largest,1.0,
real-world,1.0,
harboring,1.0,
retrospectively,1.0,
cut-off,1.0,
//,1.0,
investigator,1.0,
upon,1.0,
recist,1.0,
males,2.0,
never-smokers,2.0,
extracranial,1.0,
ec,2.0,
intracranial,2.0,
ic,2.0,
dcr,2.0,
dot,3.0,
  ,6.0,
mos,4.0,
edema,1.0,
hyperlipidemia,1.0,
gain,1.0,
fatigue,1.0,
outstanding,1.0,
ec/ic,1.0,
supports,1.0,
unprecedented,1.0,
dysregulation,1.0,
suffer,1.0,
diabetic,5.0,
polyneuropathy,1.0,
involves,1.0,
nerve,7.0,
synthetic,1.0,
arginine-rich,2.0,
exendin-,1.0,
peptide,5.0,
neuropathy,2.0,
administering,1.0,
stz,1.0,
 μg/kg,2.0,
byetta®,3.0,
neuropathic,2.0,
tactile,3.0,
stz-treated,2.0,
unlike,1.0,
naïve,3.0,
histological,1.0,
sciatic,3.0,
fibers,2.0,
ihc,1.0,
myelin,1.0,
mbp,2.0,
myelinated,1.0,
poly-arginine,1.0,
peptides,1.0,
polyneuropathies,1.0,
preterm,3.0,
longitudinal,1.0,
old,1.0,
hearing,8.0,
abr,1.0,
assr,1.0,
oae,1.0,
audiometry,2.0,
pure,1.0,
additionally,1.0,
ct,1.0,
gbj,1.0,
evaluations,1.0,
assessments,1.0,
under,3.0,
infants,3.0,
problems,1.0,
annual,1.0,
snhl,2.0,
ansd,3.0,
occurrence,1.0,
child,1.0,
kinds,1.0,
loss,1.0,
transformation,1.0,
vice,1.0,
versa,1.0,
discussed,2.0,
article,1.0,
prematurely,1.0,
born,3.0,
tends,1.0,
unstable,1.0,
deteriorate,1.0,
weeks’,1.0,
gestation,5.0,
until,1.0,
advised,1.0,
cochlear,1.0,
implantation,1.0,
introduction,2.0,
single-arm,1.0,
ascend-,2.0,
ceritinib,4.0,
anaplastic,1.0,
lymphoma,1.0,
alki–naive,1.0,
alk-rearranged,2.0,
lines,3.0,
final,2.0,
neurologically,1.0,
mg/day,1.0,
fasted,1.0,
orr,3.0,
blinded,2.0,
committee–assessed,2.0,
investigator-,1.0,
antineoplastic,1.0,
medications,2.0,
grades,1.0,
all-causality,1.0,
diarrhea,1.0,
nausea,1.0,
vomiting,1.0,
event,1.0,
discontinuation,1.0,
chemotherapy-pretreated,1.0,
alki-naive,2.0,
possibilities,1.0,
angioprotection,1.0,
osteonecrosis,3.0,
bisphosphonates,1.0,
injected,1.0,
saline,3.0,
zoledronic,5.0,
sulodexide,3.0,
constructed,1.0,
teeth,1.0,
extracted,2.0,
linear,1.0,
periodontal,1.0,
tooth,1.0,
high-frequency,1.0,
doppler,1.0,
ultrasound,1.0,
vasoactive,1.0,
min,1.0,
bony,3.0,
tissues,2.0,
head,1.0,
microcirculation,4.0,
mucous,4.0,
membranes,3.0,
periosteal,1.0,
includes,1.0,
cellular,2.0,
vasodilation,3.0,
restoration,1.0,
subcortical,1.0,
cord,4.0,
sci,7.0,
descending,2.0,
interlimb,4.0,
lumbosacral,4.0,
excitability,2.0,
humans,1.0,
ulnar,3.0,
transcutaneous,1.0,
condition-test,1.0,
paradigm,1.0,
connections,1.0,
linking,2.0,
cervical,1.0,
segments,1.0,
non-injured,1.0,
injured,1.0,
spinally,2.0,
semrs,2.0,
volitional,3.0,
leg,2.0,
muscle,2.0,
rostral,1.0,
innervation,1.0,
entry,1.0,
zones,1.0,
pools,1.0,
projections,1.0,
absence,1.0,
sub-clinical,1.0,
spared,1.0,
rehabilitation,1.0,
morphogenetic,2.0,
placenta,1.0,
roles,5.0,
placental,8.0,
hofbauer,1.0,
characterize,1.0,
steps,2.0,
intracellular,2.0,
synthesis,1.0,
secretion,4.0,
secretory,1.0,
villous,2.0,
placentas,1.0,
determined,1.0,
cytometry,2.0,
secreted,1.0,
quantified,1.0,
cytometric,1.0,
bead,1.0,
tnfα,2.0,
stimulated,1.0,
endotoxin,1.0,
il-a,1.0,
il-f,1.0,
tgf-β,1.0,
vegf,1.0,
constitutive,1.0,
age-dependent,1.0,
third-trimester,1.0,
first-trimester,1.0,
comparison,1.0,
suggested,1.0,
intraplacental,1.0,
extraplacental,2.0,
discussion,1.0,
would,1.0,
assume,1.0,
correspond,1.0,
supposedly,1.0,
confined,1.0,
storage,1.0,
lsd,1.0,
lysosome,1.0,
functionality,1.0,
plays,1.0,
vesicles,2.0,
evs,5.0,
amounts,1.0,
cargo,1.0,
sequential,1.0,
centrifugation,1.0,
сryo-electron,1.0,
cryo-em,3.0,
nanoparticle,1.0,
tracking,1.0,
nta,2.0,
scattering,1.0,
dls,2.0,
exosomal,3.0,
hsp,2.0,
tetrasponins,1.0,
profiling,2.0,
mass-spectrometry,1.0,
shotgun,1.0,
exosomes,4.0,
р,1.0,
double,1.0,
multilayer,1.0,
enriched,1.0,
сd,1.0,
exosome-associated,1.0,
proteomic,1.0,
striking,1.0,
alteration,1.0,
postural,3.0,
neuropsychiatric,2.0,
tremor,2.0,
et,8.0,
phenotypes,1.0,
et-pd,5.0,
advanced,3.0,
hoehn,1.0,
yahr,1.0,
non-motor,1.0,
stabilometry,2.0,
etpd,4.0,
milder,1.0,
posture,1.0,
walking,1.0,
discovered,1.0,
indexes,2.0,
stabilometric,2.0,
although,1.0,
helpful,1.0,
helps,1.0,
expand,1.0,
highlighted,1.0,
autophagy,3.0,
alp,8.0,
genes,5.0,
lrrk,1.0,
harbor,1.0,
α-synuclein,1.0,
snca,2.0,
degraded,1.0,
mutations/multiplications,1.0,
chaperone,1.0,
prkn,1.0,
pink,1.0,
tmem,1.0,
smpd,1.0,
ctsd,1.0,
ctsb,1.0,
crucial,1.0,
uncovering,1.0,
long-awaited,1.0,
neuroprotective,1.0,
will,3.0,
atypical,1.0,
elucidate,1.0,
dynamical,3.0,
complexity,3.0,
impulse,1.0,
emergence,3.0,
painful,1.0,
stimulus,1.0,
problem,1.0,
bifurcation,1.0,
enabled,1.0,
us,1.0,
relations,1.0,
nociceptive,2.0,
ectopic,1.0,
bursting,1.0,
discharges,2.0,
base,1.0,
potassium,1.0,
blocking,1.0,
connected,1.0,
entirely,2.0,
modification,1.0,
gating,1.0,
nav,1.0,
sodium,1.0,
comenic,1.0,
non-opioid,1.0,
analgesic,3.0,
anoceptin,1.0,
explain,1.0,
metoclopramide,8.0,
abortive,1.0,
antiemetic,1.0,
anti-cephalalgic,1.0,
elucidated,1.0,
taking,1.0,
account,1.0,
pathophysiology,1.0,
dural,3.0,
valid,1.0,
neurovascular,1.0,
nociception,2.0,
second-order,1.0,
dura-sensitive,1.0,
tcc,2.0,
infusion,2.0,
 min,1.0,
 mg/kg,2.0,
n  ,4.0,
dose-dependently,1.0,
suppressed,1.0,
maximally,1.0,
medianq-q,1.0,
p  ,2.0,
separate,1.0,
vehicle,1.0,
unable,1.0,
suppress,1.0,
anti-migraine,2.0,
therapeutic,2.0,
lipopolysaccharidein,1.0,
disturbances,1.0,
disrupts,1.0,
metabolism,1.0,
immunoassay,1.0,
simulation,1.0,
checkpoints,1.0,
predictor,1.0,
tms/tes,1.0,
eight-year,1.0,
european,2.0,
party,2.0,
drinkers,1.0,
degranulation,1.0,
influenza-sensitized,1.0,
behalf,1.0,
synucleinophaties,1.0,
cancer☆,1.0,
establishing,1.0,
glass,1.0,
real,1.0,
exenatide,1.0,
premature,1.0,
of ceritinib,1.0,
bisphosphonate,1.0,
instability,1.0,
overlapping,1.0,
